不同剂量双歧杆菌乳杆菌三联活菌片联合乳果糖治疗功能性便秘的效果比较
|
摘要
目的:探讨不同剂量双歧杆菌乳杆菌三联活菌片联合乳果糖治疗功能性便秘的效果。方法:选择某院功能性便秘患者90例,随机分为治疗1组、治疗2组以及对照组,每组各30例,对照组患者采用饮食疗法配合使用乳果糖口服;治疗1组在对照组的基础上加用双歧杆菌乳杆菌三联活菌片(剂量为:4片/次,3次/日);治疗2组同样在对照组的基础上加用双歧杆菌乳杆菌三联活菌片(剂量为:8片/次,3次/日),比较3组患者临床疗效与用药安全性。结果:治疗2组临床治疗有效率(93.33%)高于治疗1组(73.33%),治疗1组治疗有效率高于对照组(46.67%),差异有统计学意义(P<0.05);治疗后治疗2组大便性状评分与排便费力情况评分低于治疗1组,治疗1组评分低于对照组,差异有统计学意义(P<0.05);治疗后治疗2组腹胀、腹痛、食欲不振评分低于治疗1组,治疗1组症状评分低于对照组,差异有统计学意义(P<0.05);3组患者用药安全性比较差异无统计学意义(P>0.05)。结论:大剂量双歧杆菌乳杆菌三联活菌片联合乳果糖治疗功能性便秘,可有效改善患者临床症状,疗效显著,用药安全性较高。
Objective:To explore the effects of different doses of bifidobacterium-lactobacillus triple viable tablets combined with lactulose in the treatment of functional constipation.Methods:90 cases of functional constipation in a hospital were selected and randomly divided into treatment group 1, treatment group 2 and a control group, with 30 cases in each. The control group was given diet therapy combined with oral lactulose, treatment group 1 was added with bifidobacterium-lactobacillus triple viable tablets on the basis of the control group(dose: 4 tablets/time, 3 times/d), and treatment group 2 was added with bifidobacterium-lactobacillus triple viable tablets on the basis of the control group(dose: 8 tablets/time, 3 times/d). Clinical efficacy and medication safety were compared among the three groups.Results:The effective rate of clinical treatment in treatment group 2 was higher than that of the treatment group 1(93.33% vs 73.33%), and the effective rate in treatment group 1 was higher than that in the control group(73.33% vs 46.67%)(P<0.05).The scores of stool property and difficult defecation after treatment in treatment group 2 were lower than those in treatment group 1, and the scores in treatment group 1 were lower than those in the control group(P<0.05). After treatment, the scores of abdominal distension, abdominal pain and loss of appetite in treatment group 2 were lower than those in treatment group 1, and the symptom scores in treatment group 1 were lower than those in the control group(P<0.05). There was no significant difference in terms of the medication safety among the three groups(P>0.05).Conclusion: High-dose bifidobacterium-lactobacillus triple viable tablets combined with lactulose can effectively improve the clinical symptoms of patients with functional constipation, and it has remarkable efficacy and high medication safety.
Objective:To explore the effects of different doses of bifidobacterium-lactobacillus triple viable tablets combined with lactulose in the treatment of functional constipation.Methods:90 cases of functional constipation in a hospital were selected and randomly divided into treatment group 1, treatment group 2 and a control group, with 30 cases in each. The control group was given diet therapy combined with oral lactulose, treatment group 1 was added with bifidobacterium-lactobacillus triple viable tablets on the basis of the control group(dose: 4 tablets/time, 3 times/d), and treatment group 2 was added with bifidobacterium-lactobacillus triple viable tablets on the basis of the control group(dose: 8 tablets/time, 3 times/d). Clinical efficacy and medication safety were compared among the three groups.Results:The effective rate of clinical treatment in treatment group 2 was higher than that of the treatment group 1(93.33% vs 73.33%), and the effective rate in treatment group 1 was higher than that in the control group(73.33% vs 46.67%)(P<0.05).The scores of stool property and difficult defecation after treatment in treatment group 2 were lower than those in treatment group 1, and the scores in treatment group 1 were lower than those in the control group(P<0.05). After treatment, the scores of abdominal distension, abdominal pain and loss of appetite in treatment group 2 were lower than those in treatment group 1, and the symptom scores in treatment group 1 were lower than those in the control group(P<0.05). There was no significant difference in terms of the medication safety among the three groups(P>0.05).Conclusion: High-dose bifidobacterium-lactobacillus triple viable tablets combined with lactulose can effectively improve the clinical symptoms of patients with functional constipation, and it has remarkable efficacy and high medication safety.
引文
[1] 叶剑,税典奎,梁秋明,等.加味通幽汤治疗老年性功能性便秘临床疗效观察[J].湖北中医药大学学报,2016,18(1):73-75.
[2] 何馥倩,李晓冉,黄晓丽.双歧杆菌乳杆菌三联活菌片联合聚乙二醇4000散治疗老年慢性便秘的临床研究[J].华西医学,2017,14(12):1872-1875.
[3] 孟丽敏,李卫,刘伟,等.中老年功能性便秘患者症状与生活质量的相关性[J].中国老年学杂志,2017,37(7):1754-1756.
[4] 孔凡彪,邓巧明,邓洪强,等.六磨汤高位灌肠联合生物反馈治疗混合型功能性便秘45例临床观察[J].中医杂志,2017,58(19):1654-1657.
[5] 王成伟.电针深刺对功能性便秘患者排便次数及大便性状的影响[J].针刺研究,2017,42(3):254-258.
[6] 吴启富,匡彪,赵宁.枯草杆菌二联活菌联合乳果糖治疗儿童功能性便秘远期疗效观察[J].药物评价研究,2016,39(5):847-850.
[7] 童欣.酪酸梭菌活菌散联合乳果糖对小儿功能性便秘的疗效[J].中国妇幼健康研究,2016,27(1):67-69.
[8] 魏景景.麻仁软胶囊联合双歧杆菌乳杆菌三联活菌片治疗热积证功能性便秘的疗效观察[J].现代药物与临床,2018,33(2):363-367.
[9] 曹春宇,林洁,陈园.双歧杆菌四联活菌片联合莫沙必利治疗老年功能性便秘疗效观察[J].药物流行病学杂志,2016,25(4):227-229.
[2] 何馥倩,李晓冉,黄晓丽.双歧杆菌乳杆菌三联活菌片联合聚乙二醇4000散治疗老年慢性便秘的临床研究[J].华西医学,2017,14(12):1872-1875.
[3] 孟丽敏,李卫,刘伟,等.中老年功能性便秘患者症状与生活质量的相关性[J].中国老年学杂志,2017,37(7):1754-1756.
[4] 孔凡彪,邓巧明,邓洪强,等.六磨汤高位灌肠联合生物反馈治疗混合型功能性便秘45例临床观察[J].中医杂志,2017,58(19):1654-1657.
[5] 王成伟.电针深刺对功能性便秘患者排便次数及大便性状的影响[J].针刺研究,2017,42(3):254-258.
[6] 吴启富,匡彪,赵宁.枯草杆菌二联活菌联合乳果糖治疗儿童功能性便秘远期疗效观察[J].药物评价研究,2016,39(5):847-850.
[7] 童欣.酪酸梭菌活菌散联合乳果糖对小儿功能性便秘的疗效[J].中国妇幼健康研究,2016,27(1):67-69.
[8] 魏景景.麻仁软胶囊联合双歧杆菌乳杆菌三联活菌片治疗热积证功能性便秘的疗效观察[J].现代药物与临床,2018,33(2):363-367.
[9] 曹春宇,林洁,陈园.双歧杆菌四联活菌片联合莫沙必利治疗老年功能性便秘疗效观察[J].药物流行病学杂志,2016,25(4):227-229.